Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -1.590–1.590 for the period, compared to the consensus earnings per share estimate of -1.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $349.4 million.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen cut Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Zacks Research cut shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $32.00.

Fulgent Genetics Trading Down 7.0%

Shares of FLGT stock traded down $1.06 during trading on Friday, reaching $14.13. The company’s stock had a trading volume of 1,440,885 shares, compared to its average volume of 411,120. The stock’s 50-day moving average price is $16.31 and its 200 day moving average price is $22.81. Fulgent Genetics has a 1-year low of $13.46 and a 1-year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, February 27th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.The firm had revenue of $83.34 million during the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Equities research analysts predict that Fulgent Genetics will post -2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in Fulgent Genetics during the 4th quarter worth approximately $35,000. Raymond James Financial Inc. acquired a new position in Fulgent Genetics during the 2nd quarter worth approximately $49,000. Quantbot Technologies LP acquired a new position in Fulgent Genetics during the 3rd quarter worth approximately $61,000. Los Angeles Capital Management LLC acquired a new position in Fulgent Genetics during the 4th quarter worth approximately $218,000. Finally, Advisors Asset Management Inc. grew its holdings in Fulgent Genetics by 2,205.7% during the 4th quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after acquiring an additional 8,117 shares in the last quarter. 48.06% of the stock is owned by institutional investors and hedge funds.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.